<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957292</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-DIU-2015-85</org_study_id>
    <nct_id>NCT02957292</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Menstrual Bleeding Profile Among Jaydess® and Copper Intrauterine Device (IUD) Users. COLIBRI STUDY (Copper and Levonorgestrel IUD Barcelona Research Initiative).</brief_title>
  <acronym>COLIBRI</acronym>
  <official_title>A Randomized Controlled Trial to Compare the Menstrual Bleeding Profile Among Copper and 13,5mg Levonorgestrel-releasing IUD Users.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intrauterine device (IUD) is a long-term birth control method that has demonstrated high&#xD;
      contraceptive efficacy and effectiveness due to its high compliance, adherence and&#xD;
      persistence of use. The IUD has a global prevalence rate around 14% in women of reproductive&#xD;
      age.&#xD;
&#xD;
      Side effects are the main reason for IUD use discontinuation. The most common reasons for&#xD;
      copper IUD discontinuation are increased menstrual bleeding, irregular bleeding and&#xD;
      dysmenorrhea, whereas in the case of 52mg Levonorgestrel IUD are irregular bleeding and&#xD;
      amenorrhea.&#xD;
&#xD;
      In 2014, a new hormonal IUD containing13,5mg of Levonorgestrel was marketed in Spain. There&#xD;
      are many studies comparing the two Levonorgestrel IUDs. However, there is any study comparing&#xD;
      the IUD 13,5mg Levonorgestrel with classic copper IUDs.&#xD;
&#xD;
      The hypothesis of this trial is that Levonorgestrel (13,5mg) IUD users have a menstrual&#xD;
      bleeding pattern with fewer days than Copper 380 mm2 IUD users.&#xD;
&#xD;
      This is a Phase IV, national single-center, randomized 1: 1, single-blind, comparative,&#xD;
      parallel controled trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">September 15, 2020</completion_date>
  <primary_completion_date type="Actual">September 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of menstrual bleeding days</measure>
    <time_frame>90 days</time_frame>
    <description>Daily recorded during 90 days treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Menstrual bleeding</measure>
    <time_frame>90 days</time_frame>
    <description>Classified using a 5-item Likert-like scale from none to heavy, a pictorial blood loss assessment chart (PBAC), and ferritin and haemoglobin blood test determinations</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Levonorgestrel IUD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13,5 mg Levonorgestrel intrauterine device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Copper IUD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Copper (380mm2) intrauterine device</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel (13,5 mg) intrauterine device</intervention_name>
    <arm_group_label>Levonorgestrel IUD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cooper (380mm2) intrauterine device</intervention_name>
    <arm_group_label>Copper IUD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy female subject.&#xD;
&#xD;
          -  Parous or nulliparous women aged between 18 and 45 years who ask for an IUD as a&#xD;
             contraceptive method.&#xD;
&#xD;
          -  History of regular cyclic menstrual periods ranged from 21 to 35 days with&#xD;
             non-excessive menstrual blood loss.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absolute contraindications to IUD use, according to the World Health Organization&#xD;
             Medical Eligibility Criteria.&#xD;
&#xD;
          -  Contraindications to use 13,5 LNG-IUD.&#xD;
&#xD;
          -  Anemia.&#xD;
&#xD;
          -  Use of short or long-acting preparations containing sex hormones within the 12 weeks&#xD;
             before the IUD insertion.&#xD;
&#xD;
          -  Known bleeding irregularities.&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 4, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2016</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

